Vaccin gör människor sjuka - (Autism, Adhd, utvecklingsstörningar, allergier etc.)

Advisers to the U.S. Food and Drug Administration (FDA) met Thursday to discuss the future of pediatric respiratory syncytial virus (RSV) vaccines after Moderna was forced to abruptly halt clinical trials for its mRNA RSV vaccine in children ages 5-23 months.

Clinical trial data released earlier this week in an FDA briefing document showed that rather than preventing RSV disease in small children, Moderna’s vaccine likely caused higher rates of severe RSV illness in its Phase 1 clinical trial.

Moderna halted the trial in July after it was informed that two babies in the vaccine group had developed severe RSV disease. The company didn’t publicly announce that the trial was discontinued until September.

The data presented Thursday at the Vaccines and Related Biological Products Advisory Committee meeting showed that 12.5% of vaccinated children developed severe RSV disease as compared to just 5% of children in the placebo group.

Among the children who developed symptomatic RSV disease, 26.3% in the vaccinated group progressed to severe disease, while only 8.3% of those in the placebo group did.

Last month, the study titled Pharmaceutical product recall and educated hesitancy towards new drugs and novel vaccines, was published in the International Journal of Risk & Safety in Medicine. Here’s a brief summary as presented in the Abstract:

Background: Of many pharmaceutical products launched for the benefit of humanity, a significant number have had to be recalled from the marketplace due to adverse events. A systematic review found market recalls for 462 pharmaceutical products between 1953 and 2013. In our current and remarkable period of medical history, excess mortality figures are high in many countries. Yet these statistics receive limited attention, often ignored or dismissed by mainstream news outlets. This excess mortality may include adverse effects caused by novel pharmaceutical agents that use gene-code technology.

Objective: To examine key pharmaceutical product withdrawals and derive lessons that inform the current use of gene-based COVID-19 vaccines.

Methods: Selective narrative review of historical pharmaceutical recalls and comparative issues with recent COVID-19 vaccines.

Results: Parallels with past drug withdrawals and gene-based vaccines include distortion of clinical trial data, with critical adverse event data absent from high-impact journal publications. Delayed regulatory action on pharmacovigilance data to trigger market withdrawal occurred with Vioxx (rofecoxib) and is apparent with the gene-based COVID-19 vaccines.

Conclusion: Public health requires access to raw clinical trial data, improved transparency from corporations and heightened, active pharmacovigilance worldwide.

Vaccinated children have a 170% higher chance of being diagnosed with autism compared to unvaccinated children, according to a new peer-reviewed study.

The study also found that vaccinated children had a 212% greater likelihood of developing a range of other neurodevelopmental disorders, including attention-deficit/hyperactivity disorder (ADHD), epilepsy/seizures, brain inflammation and tic and learning disorders.

According to the study, the childhood vaccination schedule is likely a significant contributor to the higher rate of autism and neurodevelopmental conditions in vaccinated children.

The study of 47,155 9-year-old children enrolled in the Florida Medicaid program since birth was published on Jan. 23 in Science, Public Health Policy and the Law.

Karl Jablonowski, Ph.D., senior research scientist for Children’s Health Defense, said the paper “is unignorable simply by the soundness of its methods.”

“The sheer hazards associated with severe childhood diseases is jaw-dropping,” Jablonowski said.

Children with 11 or more vaccination visits were 340% more likely to be diagnosed with autism compared to unvaccinated children and 89% more likely to be diagnosed with autism compared to children with one vaccination visit.